
## Kathryn Lanza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7680982/publications.pdf Version: 2024-02-01



Κλτήρνη Γλήζα

#	Article	IF	CITATIONS
1	Modulation of nigral dopamine signaling mitigates parkinsonian signs of aging: evidence from intervention with calorie restriction or inhibition of dopamine uptake. GeroScience, 2023, 45, 45-63.	4.6	7
2	Genetic suppression of the dopamine D3 receptor in striatal D1 cells reduces the development of L-DOPA-induced dyskinesia. Experimental Neurology, 2021, 336, 113534.	4.1	13
3	Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats. European Journal of Neuroscience, 2021, 53, 2835-2847.	2.6	7
4	Dopamine D3 Receptor Plasticity in Parkinson's Disease and L-DOPA-Induced Dyskinesia. Biomedicines, 2021, 9, 314.	3.2	5
5	Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat. Psychopharmacology, 2020, 237, 155-165.	3.1	8
6	Dopamine receptor cooperativity synergistically drives dyskinesia, motor behavior, and striatal GABA neurotransmission in hemiparkinsonian rats. Neuropharmacology, 2020, 174, 108138.	4.1	3
7	Late aging–associated increases in L-DOPA–induced dyskinesia areÂaccompanied by heightened neuroinflammation in the hemi-parkinsonian rat. Neurobiology of Aging, 2019, 81, 190-199.	3.1	10
8	Effects of Muscarinic Acetylcholine m1 and m4 Receptor Blockade on Dyskinesia in the Hemi-Parkinsonian Rat. Neuroscience, 2019, 409, 180-194.	2.3	38
9	Pedunculopontine Nucleus Degeneration Contributes to Both Motor and Non-Motor Symptoms of Parkinson's Disease. Frontiers in Pharmacology, 2019, 10, 1494.	3.5	29
10	Serotonergic targets for the treatment of I-DOPA-induced dyskinesia. Journal of Neural Transmission, 2018, 125, 1203-1216.	2.8	28
11	Diverse serotonin actions of vilazodone reduce lâ€3,4â€dihidroxyphenylalanine–induced dyskinesia in hemiâ€parkinsonian rats. Movement Disorders, 2018, 33, 1740-1749.	3.9	19
12	Behavioral and cellular dopamine D1 and D3 receptor-mediated synergy: Implications for L-DOPA-induced dyskinesia. Neuropharmacology, 2018, 138, 304-314.	4.1	34